Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2514990123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Hathaichanok Impheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok 65000, Thailand. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Tubulin, Lung Neoplasms, Peptides. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche (ANR), Fondation pour la Recherche Médicale (FRM), Foundation MSD AVENIR.
Abstract (Originalsprache)
Detyrosination is a reversible posttranslational modification specific to α-tubulin, which has been implicated in cancer progression and invasiveness by promoting epithelial-to-mesenchymal transition. The members of the vasohibin family, VASH1 and VASH2, were previously identified as the first class of enzymes involved in catalyzing this modification. Here, we report the development of a covalent VASH inhibitor, which is characterized by high specificity and low toxicity. By combining the use of a new compound with molecular approaches in lung cancer cell lines, we find that tubulin detyrosination plays an important role in the maintenance of mesenchymal properties. We show that in the absence of VASH activity, collective cell migration and 3D spheroid formation are severely compromised. Moreover, we demonstrate that the observed phenotypes are caused by the accumulation of the important epithelial marker E-cadherin with simultaneous reduction in mesenchymal markers N-cadherin and vimentin. Taken together, our study establishes tubulin detyrosination as a promising target for the future development of anticancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok 65000, Thailand.
- Tubulin Code Team, IGH (Institute of Human Genetics) UMR 9002, Genetics, Cell Biology and Development department, Univ Montpellier, CNRS, Montpellier 34090, France.
- IBMM (Institut des Biomolécules Max Mousseron), Amino Acids, Peptides and Proteins department, Université de Montpellier, CNRS, Ecole Nationale Supérieure de Chimie de Montpellier, Montpellier 34293, France.
ORCID-Profile: Ghislain Gillard, Anthony Feral, Matthieu Simon, Maxime Louet, Muriel Amblard, Lubomir Vezenkov, Krzysztof Rogowski
Förderung
- Agence Nationale de la Recherche (ANR)
- Fondation pour la Recherche Médicale (FRM)
- Foundation MSD AVENIR
- CANCEROPOLE GSO
- Naresuan University (NU)
- Franco-Thai Young Talent research fellowship
- PHC Siam 2024-2025
Zitieren
APA
Impheng, H., Gillard, G., Numnoi, N., Feral, A., Simon, M., Louet, M., Amblard, M., Juge, F., Vezenkov, L., & Rogowski, K. (2026). Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2514990123
Vancouver
Impheng H, Gillard G, Numnoi N, Feral A, Simon M, Louet M, et al. Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2514990123
BibTeX
@article{Impheng2026,
author = {Impheng, Hathaichanok and Gillard, Ghislain and Numnoi, Nuttanid and Feral, Anthony and Simon, Matthieu and Louet, Maxime and Amblard, Muriel and Juge, François and Vezenkov, Lubomir and Rogowski, Krzysztof},
title = {Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2514990123}
}
EUVIMED